Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Aug 1.

Published in final edited form as: Breast Cancer Res Treat. 2019 May 3;176(3):545–556. doi: 10.1007/s10549-019-05258-0

Table 2.

Clinical stages and distribution

		CSLEX
	levels	High	Low	P value
Breast Cancer Type	HD	3(7%)	40(93%)	.0106
	MBC	21(33.3%)	42(66.7%)	.1366^*
	DCIS	5(19.2%)	21(80.8%)
	nMBC	32(20.8%)	122(79.2%)
Clinical Stage	HD	3(7%)	40(93%)	.0202
	0	5(19.2%)	21(80.8%)	.1926^*
	I	8(16.7%)	40(83.3%)
	II	8(17%)	39(83%)
	III	16(27.1%)	43(72.9%)
	MBC	21(33.3%)	42(66.7%)
Hormone	Negative	28(36.4%)	49(63.6%)	.0019
	Positive	30(18.1%)	136(81.9%)
HER2	Negative	35(22.9%)	118(77.1%)	.6361
	Positive	23(25.6%)	67(74.4%)
TNBC	Non-TNBC	42(21.3%)	155(78.7%)	.0538
	TNBC	16(34.8%)	30(65.2%)

^*

Excluding HD cases